dc.contributor | Universidade Federal de São Paulo (UNIFESP) | |
dc.creator | Garcia, Riberto | |
dc.creator | Machado, Paula Goulart Pinheiro | |
dc.creator | Felipe, Claudia Rosso | |
dc.creator | Park, Sung In | |
dc.creator | Spinelli, Glaucio Amaral | |
dc.creator | Franco, Marcello Fabiano de | |
dc.creator | Tedesco-Silva Junior, Hélio | |
dc.creator | Pestana, Jose Osmar Medina | |
dc.date.accessioned | 2015-06-14T13:36:50Z | |
dc.date.accessioned | 2019-05-24T16:35:26Z | |
dc.date.available | 2015-06-14T13:36:50Z | |
dc.date.available | 2019-05-24T16:35:26Z | |
dc.date.created | 2015-06-14T13:36:50Z | |
dc.date.issued | 2007-04-01 | |
dc.identifier | Brazilian Journal of Medical and Biological Research. Associação Brasileira de Divulgação Científica, v. 40, n. 4, p. 457-465, 2007. | |
dc.identifier | 0100-879X | |
dc.identifier | http://repositorio.unifesp.br/handle/11600/3646 | |
dc.identifier | S0100-879X2007000400003.pdf | |
dc.identifier | S0100-879X2007000400003 | |
dc.identifier | 10.1590/S0100-879X2007000400003 | |
dc.identifier | WOS:000245440000003 | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/2822898 | |
dc.description.abstract | Chronic allograft nephropathy is among the major causes of graft loss even in low-risk kidney transplant recipients and correlates with acute nephrotoxic events during the first year post-transplant. Therefore, calcineurin inhibitor-free regimens may improve patient and graft survival among recipients of living-related kidney transplants. To confirm this hypothesis, we evaluated the efficacy and safety of two calcineurin inhibitor-free regimens in 92 low-risk recipients of one-haplotype living-related kidney transplants. Immunosuppression consisted of tacrolimus, azathioprine and prednisone (group I, GI, N = 38), 2 doses of daclizumab, mycophenolate mofetil (MMF), and prednisone (GII, N = 33) and 2 doses of daclizumab, MMF, sirolimus and prednisone (GIII, N = 21). At 12 months, treatment failure (biopsy-confirmed acute rejection, graft loss or death) was higher in GII compared to GIII and GI (54.5 vs 24.0 vs 13.1%, P < 0.01, respectively). In patients of black ethnicity the incidence of acute rejection was 25 vs 83.3 vs 20% (P = 0.055), respectively. Patient and graft survival was comparable. There were no differences in mean creatinine or calculated creatinine clearance at 12 months. Overall incidence of post-transplant diabetes mellitus (3.3%) and cytomegalovirus disease (4.3%) was similar in all groups. Further development of effective calcineurin inhibitor-free regimens should exclude patients of black ethnicity and may need full-induction therapy, perhaps with depleting agents, and concentration-controlled use of sirolimus and MMF. | |
dc.language | eng | |
dc.publisher | Associação Brasileira de Divulgação Científica | |
dc.relation | Brazilian Journal of Medical and Biological Research | |
dc.rights | Acesso aberto | |
dc.subject | Tacrolimus | |
dc.subject | Mycophenolate mofetil | |
dc.subject | Sirolimus | |
dc.subject | Kidney transplantation | |
dc.subject | Acute rejection | |
dc.subject | Clinical trial | |
dc.title | Exploratory calcineurin inhibitor-free regimens in living-related kidney transplant recipients | |
dc.type | Artículos de revistas | |